EZZ Life Science Holdings Ltd Quarterly Report Q4 FY26
Key points
- Customer receipts increased by 10% to $9.8m
- Operating cash outflow reduced significantly to $0.05m
- Expanded Australian retail distribution by 20 new locations
- Extended MeTime product range with two new products
- Published research co-funded with the University of Auckland
Full summary
EZZ Life Science Holdings Ltd released its Quarterly Activity Report for Q4 FY26, highlighting a 10% increase in customer receipts to $9.8 million, a significant reduction in operating cash outflow to $0.05 million, and expansion of its Australian retail distribution network by 20 new locations. The company extended its MeTime product range with two new Australian-made formulations and published research co-funded with the University of Auckland. Cash and cash equivalents stood at $9.7 million at the end of the quarter, with the company remaining debt-free (excluding lease liabilities). CEO Mark Qin emphasized the company's focus on disciplined growth, product innovation, and financial discipline amidst challenging trading conditions.
Guidance
Customer receipts $9.8m, operating cash outflow $0.05m, cash and cash equivalents $9.7m
Outlook
EZZ plans to continue its growth strategy focusing on product innovation, selective channel expansion, and strengthened distribution partnerships for FY27.
Summary generated by a large language model. Please interpret with care.